Here are a few top buzzing midcap stocks picked by CNBC-TV18's analysts in trade today -- Indiabulls Real Estate, Sun Pharmaceutical, Unichem Lab, Dr Reddys Laboratories, Natco Pharma, Punj Lloyd, Reliance Defence and DCB Bank.
The US FDA has recorded 11 observations at Sun Pharmaceutical's Dadra based formulations manufacturing site.
Vijay Chopra of enochventures.com advises selling Orchid Pharma.
For investors, the Sun Pharma stock has long stood for a focus on growth, both through organic and inorganic routes. Is this lack of focus through unrelated investments the reason for its underperformance?
Aurobindo Pharma, Glenmark and Sun Pharmaceutical gained 2-4 percent intraday after the US health regulator has given approval for antihyperlipidemic drug Rosuvastatin calcium tablets.
Headwinds plaguing the country's largest drug-maker Sun Pharmaceutical will continue for next two-three quarters owing to pricing pressures and regulatory issues dogging its Halol plant, says a report
If the offer is fully subscribed, the number of Taro shares to be purchased in the offer represents approximately 4.6 to 5.3 percent of the unit's total outstanding shares.
Tata Motors, Cairn India and Sun Pharmaceutical were the top buys, while NHPC, Jaiprakash Power Ventures and SpiceJet were the top sells by the Kotak Mahindra Mutual Fund.
Analysts tracking the sector say Sun Pharma already has 50 percent of the market share in this drug which will get a further boost after this development.
Jitendra Sriram, MD & Head of Research of HSBC India is of the view that one may prefer Sun Pharmaceutical and Lupin from the pharma space.
According to Sudarshan Sukhani of s2analytics.com, one may buy Cipla, Lupin, Sun Pharmaceutical and Dr Reddys Laboratories at current level with a long term view.
Many firms in capital-intensive industries such as infrastructure, manufacturing and metals that borrowed in offshore markets lack an overseas income stream to buffer their currency exposure, and the impact is expected to become clear in the current reporting season
Hikma Pharmaceuticals on Monday raised its full-year revenue forecast citing strong sale of a generic antibiotic also sold by Sun Pharma
According to Sudarshan Sukhani of s2analytics.com, Sun Pharmaceutical is a buying opportunity.
A Supreme Court ruling in 2011 found that pharmaceutical companies that make branded drugs are liable for inadequacies in safety warnings of a medicine's label, but not the makers of cheaper copies of those medicines.
Parag Doctor, Head - Trading Strategies at Keynote Capital's advises to exit Sun Pharmaceutical. The stock may fall to Rs 900 in immediate term, Doctor adds.
The government will release January-March quarter GDP on Friday, which is expected to confirm the economy grew at its slowest pace in a decade in the 2012/13 fiscal year.
Maruti is a play on the yen more than anything, says Sanjeev Prasad of Kotak Institutional Equities. He is bearish on FMCG stocks, and says will not buy them at the current price to earning multiples of 30-35 times.
Software services firm HCL Technologies today appointed Keki Mistry as Director on its board. With Mistry's appointment, the board strength of the company increases to 11 Directors, including nine independent ones, the company said in a statement.
Sudarshan Sukhani, s2analytics.com is of the view that one buy Sun Pharmaceutical.
Shares in Sun Pharmaceutical Industries, India's most valued drugmaker, rose as much as 2.5 percent after its unit agreed to buy the generic drugs business of US-based URL Pharma from Japan's Takeda Pharmaceutical Co.
Technical resistance for Nifty is seen at 5,950 while for the Bank Nifty it is at 12,500. Once both indexes breach these levels only then one can expect a next big move.
Sun Pharmaceutical Industries Ltd said it will acquire U.S. dermatology company Dusa Pharmaceuticals Inc for about USD 230 million to gain access to its light-based skin treatment platform.
More steam left in pharma space, says Samir Lumba, JM Financial.
Shares in Sun Pharmaceutical Industries fall 1.6 percent on worries the drug maker will soon see an end to its temporary arrangement to supply cancer drug Doxil in the United States.